Member States shall take all necessary measures to ensure that the manufacturing and purifying processes used in the preparation of medicinal products derived from human blood or human plasma are properly validated, attain batch-to-batch consistency and guarantee, insofar as the state of technology permits, the absence of specific viral contamination. To this end manufacturers shall notify the competent authorities of the method used to reduce or eliminate pathogenic viruses liable to be transmitted by medicinal products derived from human blood or human plasma. The competent authority may submit samples of the bulk and/or the medicinal product for testing by a State laboratory or a laboratory designated for that purpose, either during the examination of the application pursuant to Article 19, or after a marketing authorization has been granted.
Art. 115 Directive (EU) 2001/83
In forcecited 2×
Commission Regulation (EC) No 658/2007 of 14 June 2007 concerning financial penalties fo…8Law
… 44 odst. 1 nařízení (ES) č. 726/2004; b) prováděním inspekcí nebo jiných opatření dozoru v souladu s články 111 až 115 směrnice 2001/83/ES a s články 80, 81 a 82 směrnice 2001/82/ES. Žádosti musí být písemné a musí …
Commission Regulation (EC) No 658/2007 of 14 June 2007 concerning financial penalties fo…8Law
… 44(1) of Regulation (EC) No 726/2004; (b) by performing inspections or other supervisory measures in accordance with Articles 111 to 115 of Directive 2001/83/EC and Articles 80, 81 and 82 of Directive 2001/82/EC. Requests shall be …